obeticholic acid - Profile

What are the generic sources for obeticholic acid and what is the scope of freedom to operate?

Obeticholic acid is the generic ingredient in two branded drugs marketed by Apotex, Lupin, MSN, and Intercept Pharms Inc, and is included in four NDAs. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Obeticholic acid has one hundred and twenty-three patent family members in thirty-seven countries.

There is one tentative approval for this compound.

Summary for obeticholic acid

International Patents:	123
US Patents:	7
Tradenames:	2
Applicants:	4
NDAs:	4
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for obeticholic acid

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for obeticholic acid

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Generic filers with tentative approvals for OBETICHOLIC ACID

Applicant	Application No.	Strength	Dosage Form
		10mg	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for OBETICHOLIC ACID

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OCALIVA	Tablets	obeticholic acid	5 mg and 10 mg	207999	5	2020-05-27

US Patents and Regulatory Information for obeticholic acid

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex	OBETICHOLIC ACID	obeticholic acid	TABLET;ORAL	214862-001	May 30, 2023		DISCN	No	No
Apotex	OBETICHOLIC ACID	obeticholic acid	TABLET;ORAL	214862-002	May 30, 2023		DISCN	No	No
Lupin	OBETICHOLIC ACID	obeticholic acid	TABLET;ORAL	214980-001	May 30, 2023		DISCN	No	No
Lupin	OBETICHOLIC ACID	obeticholic acid	TABLET;ORAL	214980-002	May 30, 2023		DISCN	No	No

Expired US Patents for obeticholic acid

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-002	May 27, 2016
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-002	May 27, 2016
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-001	May 27, 2016
Intercept Pharms Inc	OCALIVA	obeticholic acid	TABLET;ORAL	207999-002	May 27, 2016

EU/EMA Drug Approvals for obeticholic acid

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
ADVANZ PHARMA Limited	Ocaliva	obeticholic acid	EMEA/H/C/004093Ocaliva is indicated for the treatment of primary biliary cholangitis (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA.	Authorised	no	no	yes	2016-12-12

International Patents for obeticholic acid

Country	Patent Number	Title	Estimated Expiration
Australia	2020202405	Preparation, uses and solid forms of obeticholic acid
Japan	2020125317	オベチコール酸の調製、使用および固体形態 (PREPARATION, USES AND SOLID FORMS OF OBETICHOLIC ACID)
Australia	2017204057	Preparation, Uses and Solid Forms of Obeticholic Acid
Japan	2015521621	オベチコール酸の調製、使用および固体形態

Supplementary Protection Certificates for obeticholic acid

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1392714	1790020-0	Sweden		PRODUCT NAME: OBETICHOLIC ACID; REG. NO/DATE: EU/1/16/1139 20161215
1392714	23/2017	Austria		PRODUCT NAME: OBETICHOLSAEURE, DESSEN PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE ODER AMINOSAEURE-KONJUGATE; REGISTRATION NO/DATE: EU/1/16/1139 20161212
1392714	132017000061826	Italy		PRODUCT NAME: ACIDO OBETICOLICO(OCALIVA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1139, 20161215
1392714	598	Finland

Obeticholic Acid: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Obeticholic acid (OCA), marketed as Ocaliva, is a synthetic bile acid derivative developed for the treatment of primary biliary cholangitis (PBC) and under investigation for other hepatic and metabolic conditions. Since its FDA approval in 2016, OCA has experienced a growing market presence amid increasing demand for therapies addressing chronic liver diseases. This report examines the current market landscape, key investment considerations, competitive dynamics, and projected financial trajectory for OCA over the next decade.

---

What Is Obeticholic Acid and Why Is It a Focus for Investment?

Obeticholic acid (OCA):

• Chemical Class: Farnesoid X Receptor (FXR) agonist
• Indications: Primarily approved for PBC; under clinical development for NASH, OA, and other fibrotic liver diseases
• Market Authorization: Approved in the U.S. (FDA, 2016), EU (EMA, 2017), and other jurisdictions
• Market Potential: Driven by rising prevalence of liver diseases, limited current treatments for NASH, and expanding clinical applications

---

Market Dynamics

1. Current Market Landscape

Market Segment	Status	Key Players	Estimated Market Size (2023)	Growth Drivers
Primary Biliary Cholangitis (PBC)	Established, moderate size	Intercept Pharmaceuticals (AbbVie license), other generic manufacturers	~$300 million (global)	Rare disease, high unmet need
Non-Alcoholic Steatohepatitis (NASH)	Emerging, high-growth	Intercept, Genfit, Novartis, others	~$600 million (projected by 2027)	Rising NASH prevalence, lack of approved therapies
Cholestatic and Fibrotic Liver Diseases	Early clinical stage	Various biotech firms	Limited; potential growth	Expansion into broader indications

2. Key Market Drivers and Restraints

Drivers	Restraints
Increasing prevalence of NASH and F2/F3 fibrosis	High clinical failure rates; long development cycles
Limited current treatment options for NASH	Regulatory uncertainties for new indications
Advances in biomarker and diagnostic tech	Pricing pressures and reimbursement hurdles
Aging global population	Cost of therapy and market access barriers

3. Regulatory and Reimbursement Environment

Jurisdiction	Status	Reimbursement Outlook	Challenges
U.S. (FDA)	Approved for PBC; investigational for NASH	Payers are increasingly cautious but open to value-based pricing	Demonstrating long-term expense savings
EU	Approved for PBC; clinical trials for NASH	Similar to US; depends on proven clinical benefit	Cross-country reimbursement disparities
Japan and APAC	Approvals ongoing or pending	Emerging market with high growth potential	Market entry hurdles and local regs

---

Financial Trajectory: Forecast and Investment Outlook

1. Revenue Projections (2023-2033)

Year	PBC Revenue ($ millions)	NASH Revenue ($ millions)	Total Revenue ($ millions)	Assumptions
2023	300	0	300	U.S. market, limited NASH sales
2025	400	150	550	Expanded NASH clinical approvals and launches
2028	500	500	1,000	Broader indications, increased penetration
2030	600	800	1,400	Market saturation, new geographic expansion
2033	650	1,200	1,850	Continued growth, new formulations or delivery methods

2. Profitability and Cost Considerations

Element	Estimated Impact
Development Costs	$200-$300 million for NASH trials over 5 years
Manufacturing Expenses	Marginally decreasing with scale; estimated at 20% of sales
Marketing & Distribution	15-20% of revenue, with higher investment for NASH launches
Regulatory and Reimbursement Strategies	Ongoing costs; potential for high ROI with successful approval and coverage

3. Competitive Analysis

Competitors	Pipeline Status	Key Differentiators	Market Share (Estimated 2023)
Intercept Pharmaceuticals (AbbVie license)	Approved (PBC)	First-mover advantage, clinical validation	~60% (PBC)
Novartis (NASH pipeline)	Phase 2/3	Broader indication pipeline	N/A
GENFIT (NASH candidate)	Phase 2	Biomarker-driven patient selection	N/A
Others	Various	Innovation and combination therapies	N/A

4. Investment Risks and Opportunities

Risks	Opportunities
Clinical trial failures, especially in NASH	Large unmet need; high premium for effective therapies
Slow regulatory acceptance for new indications	Early partnerships and licensing potential
Competitive erosion with emerging therapies	Strategic collaborations and geographic expansion
Market access and reimbursement hurdles	Value-based pricing strategies

---

Comparison with Adjacent Markets and Therapeutics

Aspect	Obeticholic Acid (OCA)	Alternative Therapies
Approved Indication	PBC (FDA, EMA)	Ursodeoxycholic acid (standard of care in PBC)
Clinical Stage (NASH)	Yes (Phase 3)	Many pipeline candidates; some in Phase 2/3
Mechanism of Action	FXR agonist	Diverse: antioxidants, anti-fibrotics, metabolic agents
Market Penetration	Limited but expanding	Higher for PBC, nascent for NASH

---

Regulatory Environment and Policy Considerations

Policy Area	Impact on Investment
Accelerated approval pathways	May reduce time to market for NASH drugs
Reimbursement policies	Critical for revenue realization
Orphan drug designations	Possible for PBC; enhances exclusivity
Global approvals	Expand market access; requires compliance strategies

---

Key Drivers of Future Growth

• Growing prevalence of NASH and F3-F4 fibrosis
• Expanded clinical development for secondary indications
• Strategic partnerships with biotech and pharma firms
• Technological innovations such as combination therapies and biomarker-guided patient stratification
• Increasing inclusion in clinical guidelines for liver disease management

---

Summary Tables

Market Size Estimates (2023-2033)

Year	PBC Market ($ millions)	NASH Market ($ millions)	Total ($ millions)
2023	300	0	300
2025	400	150	550
2028	500	500	1,000
2030	600	800	1,400
2033	650	1,200	1,850

Risks and Opportunities Summary

Risks	Opportunities
Clinical trial failures	First-mover advantage in niche markets
Regulatory hurdles	Expanding indications for fibrosis and NASH
Market access challenges	Strategic alliances and licensing deals
Competition from other FXR agonists	Differentiation through biomarker and combination therapies

---

Key Takeaways

• Obeticholic acid remains a pivotal drug with a substantial market for PBC, facing moderate but stable competition.
• The promising NASH pipeline and expanding indications pose significant growth opportunities but are contingent on successful clinical trials and regulatory approval.
• Investment viability depends on navigating regulatory policies, reimbursement landscapes, and competitive innovations.
• The forecast indicates potential triple growth in revenues from 2023 to 2033, driven mostly by NASH expansion.
• Strategic partnerships and technological advancements are critical in improving market penetration and extending patent exclusivity.

---

FAQs

1. What are the primary applications of obeticholic acid?

Obeticholic acid is primarily approved for primary biliary cholangitis (PBC). It is also under clinical investigation for non-alcoholic steatohepatitis (NASH), liver fibrosis, and other cholestatic liver diseases.

2. How does obeticholic acid compare to other FXR agonists?

OCA was the first FXR agonist approved for PBC, giving it a first-mover advantage. Competitors like tropifexor and EDP-305 are in development, but none have yet gained approval, making OCA a dominant player currently.

3. What are the main challenges for the expansion of OCA into NASH?

Major challenges include demonstrating long-term safety and efficacy, meeting regulatory requirements, and convincing payers of the therapy's cost-effectiveness in a competitive and evolving market.

4. How significant are regulatory policies in influencing OCA's market growth?

Regulatory policies, including accelerated approvals and orphan designations, significantly impact market entry timing, reimbursement, and patent protections, thereby influencing revenue potential.

5. What are the strategic considerations for investors in OCA?

Investors should monitor ongoing clinical trial outcomes, regulatory developments, partnership agreements, and competitive dynamics, especially regarding NASH pipeline progress and market acceptance.

---

References

1. FDA. FDA approval of obeticholic acid for PBC. 2016.
2. European Medicines Agency (EMA). Marketing authorization for Ocaliva. 2017.
3. Market research reports. Global NASH market projections, 2023-2033.
4. Intercept Pharmaceuticals. Clinical pipeline and partnership details. 2022.
5. ClinicalTrials.gov. NASH and fibrosis clinical trial data. 2023.

---

This comprehensive analysis provides business decision-makers with essential insights into obeticholic acid’s current market position, growth prospects, and strategic investment considerations.